#Oxbryta

[injurylawsuitconnect]

🚨 If you suffered injury (e.g., vaso-occlusive sickle cell crisis, stroke or organ damage) or someone you love died after taking Oxbryta, you may be eligible to recover compensation from an Oxbryta recall injury lawsuit case or settlement claim. ⚡https://injurylawsuitconnect.com/oxbryta-recall-lawsuit-sickle-cell-crisis-vaso-occlusive-crisis/

[biotech-news-feed]

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and halted clinical trials of the drug as data indicate a high risk of severe adverse events. #BioTech #science

[regenhealthsolutions]

Pfizer Voluntarily Withdraws All Lots of Sickle Cell Disease Treatment OXBRYTA® (voxelotor) From Worldwide Markets

 Pfizer Inc. (NYSE: PFE) announced today that it is voluntarily withdrawing all lots of OXBRYTA ® (voxelotor) for the treatment of sickle cell disease (SCD) at this time, in all markets where it is approved. Pfizer is also discontinuing all active voxelotor clinical trials and expanded access programs worldwide. Pfizer’s decision is based on the totality of clinical data that now indicates the…

[healthcaretrends23]

The sickle cell disease treatment market growth driven by increase in prevalence of sickle cell disease, rise in pipeline products, and surge in demand for sickle cell disease drugs. In addition, expansion of R&D pipeline, ongoing medicine approvals, and strong growth potential in unexplored new markets are expected to provide numerous sickle cell disease treatment market opportunity for the market growth during the forecast period. For instance, in November 2019, FDA approved Oxbryta (voxeletor), to treat the sickle cell disease, which is expected to boost the market growth.

[itswallstreetpr]

Pfizer Inc (NYSE: PFE) To Acquire Global Blood Therapeutics For $5 Billion

According to sources familiar with the matter, the Wall Street Journal reported that Pfizer Inc (NYSE: PFE) was in advanced discussions to acquire pharmaceutical company Global Blood Therapeutics (NASDAQ: GBT) for $5 billion. Pfizer, too, acquired Global Blood Therapeutics  Pfizer wants to close a deal soon, but there are still other interested parties, according to the article. Global Blood Therapeutics, which manufactures Oxbryta, the blood disorder medication, saw its shares jump 44%  on Friday afternoon to a two-year high. As of Thursday's closing, the company's market cap was $3.12 billion. A spokesman for Global Blood stated the company does not "comment on market rumors or speculation," while Pfizer declined to respond on the matter. With plenty of cash left over after selling its COVID-19 vaccine, New York-based Pfizer is searching for deals that may generate billions of dollars annual sales by 2030. Its $11.6 billion acquisition of migraine medication manufacturer Biohaven Pharmaceutical Holding (NASDAQ: BHVN) in May was the most recent in a series of purchases that also included Trillium Therapeutics and Arena Pharmaceuticals in recent years. Oxbryta received approval last year for sickle cell disease management  In 2019, the US government approved Global Blood's Oxbryta to manage sickle cell disease in individuals aged 12 and over. The oral medication was approved in December 2021 to treat the illness in younger children. The drug's sales increased by almost 50% to $194.7 million in 2021. After a gloomy start to the calendar year, when a lack of significant purchases and clinical-stage treatment failures lowered investor morale and restricted funding, the biotech dealmaking pace has recently picked up again. Also, Amgen Inc (NASDAQ: AMGN) also decided to purchase ChemoCentryx Inc on Thursday for $3.7 billion to obtain access to a possible breakthrough medication for inflammatory illnesses. AstraZeneca's $39 billion acquisition of Alexion Pharmaceuticals in 2020 has put the realm of immune diseases in the limelight. The deal, which was announced before trading opened, will also give the corporation control of at least two investigational immune disorders medicines. Read the full article

[unbiasedph]

Pfizer in talks on $5B buyout of pharma with sickle-cell

Pfizer in talks on $5B buyout of pharma with sickle-cell

GBT's sickle-cell treatment, marketed as Oxbryta, was authorized for those over 12 years old in 2019, but gained federal approval in December for children aged four to 11 Read Full News @ Daily Tribune

[digicloudm]

GBT Stock Rockets On Rumors Pfizer Could Buy It For $5 Billion

GBT Stock Rockets On Rumors Pfizer Could Buy It For $5 Billion

Rumors that Pfizer (PFE) is in “advanced talks” to acquire Global Blood Therapeutics (GBT) for about $5 billion sent GBT stock flying for a second consecutive day Friday. X Global Blood Therapeutics makes a sickle cell disease treatment called Oxbryta for patients age 4 and older. According to the Wall Street Journal, Pfizer is set to finalize the deal for Global Blood in the coming days. Other…

[market-insider]

Hemoglobinopathies Market Worth $15.7 Billion By 2028

The global hemoglobinopathies market size is expected to reach USD 15.7 billion by 2028, according to a new report by Grand View Research, Inc. It is expected to expand at a CAGR of 10.8% from 2021 to 2028. Increasing awareness regarding hemoglobinopathies and government initiatives to diagnose the diseases at an early stage are expected to propel the market growth over the forecast period. Moreover, increasing R&D investment, the presence of a promising drug pipeline, and technologically advanced diagnostics platforms are expected to boost the growth of the market.

The development of novel curative technologies, such as CRISPR/Cas9 and hematopoietic stem cell transplantation, coupled with a promising pipeline, is expected to propel market growth. Moreover, the presence of regulatory agencies, such as the FDA, which are working toward improving drug approval rate by granting accelerated approval for hemoglobinopathies drugs, is expected to drive the market. For instance, in 2019, the FDA has approved four novel drugs: Reblozyl by Bristol-Myers Squibb Company, Adakveo by Novartis AG, Zynteglo by bluebird bio, Inc., and Oxbryta by Global Blood Therapeutics, Inc. for the treatment of hemoglobinopathies.

Initiatives such as the Sickle Cell Awareness Initiative (SCAI) are working toward educating the people about the disease, which will increase the diagnosis and treatment rate. SCAI also raises funds for individuals affected with sickle cell diseases (SCDs) and provides research funding. Moreover, governments of Middle Eastern and Asian countries provide funds for R&D of hemoglobinopathies treatment. For instance, various programs undertaken by governments, such as thalassemia screening in neonates and providing medicines, are impacting the market growth positively.

The high patient population in low-income countries has encouraged market players and non-profit organizations to launch several initiatives to improve the access to the therapy. For instance, in February 2019, the Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) was launched by Global Blood Therapeutics, Inc. in order to provide research funding for novel SCD projects, with an aim to expand the access to optimal healthcare for sickle cell disease.

Biopharmaceutical companies are collaborating with nonprofit organizations to promote public awareness about hemoglobinopathies. For instance, in June 2018, the Sickle Cell Disease Association of America partnered with Emmaus Life Sciences, Inc. to provide online educational tools to sickle cell patients, friends, clinicians, caregivers, and researchers for spreading awareness about complications associated with SCD.

An increase in investment and funding for the development of novel therapies to treat hemoglobinopathies will further boost the market growth over the forecast period. The National Heart, Lung, and Blood Institute (NHLBI) has significantly invested in research & development in sickle cell disease. The NHLBI supports research work through various initiatives. Furthermore, private funding such as the Bronx Blood Research Fund (BBRF) provides a platform for research and management of thalassemia and other hemoglobinopathies.

Gene therapy has emerged as a promising treatment option for managing hemoglobin disorder as it targets the underlying genetic cause of the condition through the administration of one-time gene therapy and significantly reduces the need for blood transfusions. The current pipeline of gene therapy products includes CTX001 (CRISPR Therapeutics), BIVV003 (Sangamo Therapeutics, Inc. & Bioverativ Inc), and HGB-206 (bluebird bio, Inc).

Gain deeper insights on the market and receive your free copy with TOC now @:

https://www.grandviewresearch.com/industry-analysis/hemoglobinopathies-market/request/rs15

[biotech-news-feed]

Referral: Oxbryta, Voxelotor Article 20 procedures Procedure started #BioTech #science

[soniaaristo]

Two New Drugs Help Relieve Sickle-Cell Disease. But Who Will Pay? Adakveo and Oxbryta could be revolutionary treatments, but each costs about $100,000 per year and must be taken for life.. via NYT Health

[completefamilyeyecare]

Two New Drugs Help Relieve Sickle-Cell Disease. But Who Will Pay?

By BY GINA KOLATA Adakveo and Oxbryta could be revolutionary treatments, but each costs about $100,000 per year and must be taken for life. Published: December 7, 2019 at 12:04PM from NYT Health https://www.nytimes.com/2019/12/07/health/sickle-cell-adakveo-oxbryta.html?partner=IFTTT https://completeeyecaremn.com/

[izayoi1242]

Two New Drugs Help Relieve Sickle-Cell Disease. But Who Will Pay?

By BY GINA KOLATA Adakveo and Oxbryta could be revolutionary treatments, but each costs about $100,000 per year and must be taken for life. Published: December 8, 2019 at 03:04AM from NYT Health https://ift.tt/3520H25 via IFTTT

[womannewsagency]

دواء أميركي جديد يبشر بالأمل في علاج مرض خلايا الدم المنجلية

وافقت إدارة الغذاء والدواء الأميركية (FDA)، وهي الوكالة الأميركية المنظِمة للأدوية والعلاجات، على دواء جديد أنتجته إحدى الشركات بولاية كاليفورنيا لعلاج مرض خلايا الدم المنجلية (Sickle Cell)، وهو اضطراب وراثي في الدم يسبب الألم ويهدد الأرواح، ويُعرف بعدد من الأسماء الأخرى من بينها: فقر الدم المنجلي، والأنيميا المنجلية. قال بريت بي جيروير، القائم بأعمال مفوض إدارة الغذاء والدواء الأميركية، في 25 تشرين الثاني/نوفمبر، عندما وافقت الوكالة على دواء أوكسبريتا (Oxbryta) للمرضى الذين تزيد أعمارهم عن 12 source http://wonews.net/ar/index.php?act=post&id=24248

[sicklecellmn]

Rp @drzsicklecell Let’s not kid ourselves. Improving anemia in #sicklecell results in meaningful change. Excited about Oxbryta! #globalbloodtherapeutics #accesstocare https://www.instagram.com/p/B5gJDZGAe6B/?igshid=ilxo6jovrr5o